Gilead Sciences said Wednesday that its cancer drug Trodelvy prolonged the survival of women with the most common form of breast cancer by just under 30% — a clinical trial result that could lead to a better treatment option for patients with advanced disease and strengthen the drug’s commercial outlook.
In the study, called TROPICS-02, Trodelvy showed a median overall survival of 14.4 months compared to 11.2 months for comparator chemotherapy. The survival benefit of 3.2 months was statistically significant and translated into a 21% reduction in the risk of death.
The 543 women enrolled in the study were diagnosed with HR-positive, HER2-negative metastatic breast cancer, which makes up about 70% of cases. All of the patients had advanced breast cancer that was no longer responsive to several lines of prior therapy, including hormone treatments, CDK4/6 inhibitors, and chemotherapy.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect